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Abstract: Mithramycin (MTM), a natural product of soil bacteria from the Streptomyces
genus, displays potent anticancer activity but has been limited clinically by severe side effects
and toxicities. Engineering of the MTM biosynthetic pathway has produced the 3-side-chainmodified analogs MTM SK (SK) and MTM SDK (SDK), which have exhibited increased
anticancer activity and improved therapeutic index. However, these analogs still suffer from
low bioavailability, short plasma retention time, and low tumor accumulation. In an effort to aid
with these shortcomings, two nanoparticulate formulations, poly(ethylene glycol)-poly(aspartate
hydrazide) self-assembled and cross-linked micelles, were investigated with regard to the
ability to load and pH dependently release the drugs. Micelles were successfully formed with
both nanoparticulate formulations of each drug analog, with an average size of 8.36 ± 3.21 and
12.19 ± 2.77 nm for the SK and SDK micelles and 29.56 ± 4.67 nm and 30.48 ± 7.00 nm for
the SK and SDK cross-linked micelles respectively. All of the drug-loaded formulations showed
a pH-dependent release of the drugs, which was accelerated as pH decreased from 7.4 to 5.0.
The micelles retained biological activity of SK and SDK entrapped in the micelles, suppressing
human A549 lung cancer cells effectively.
Keywords: drug delivery, polymer micelles, controlled release, MTM, cancer chemotherapy
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Mithramycin (MTM), an aureolic acid-type polyketide antibiotic produced naturally by
soil bacteria from the Streptomyces genus, exhibits anticancer activity by cross-linking
GC-rich DNA and shutting down proto-oncogenes, particularly those triggered by Sp
(specificity protein) transcription factors, eg, Sp1 and Sp3.1–5 Overexpression of Sp1
has been observed in several cancers and has been linked to the control of cell growth,
survival, and differentiation, all of which are important in cancer progression.6–8 MTM
has been used clinically in the past to treat testicular cancer, Paget’s bone disease, and
hypercalcemia but has been severely limited by its poor bioavailability and toxic side
effects such as hepatic, gastrointestinal, bone marrow, and renal toxicities.9–13 In order
to address these issues, extensive combinatorial biosynthesis has been performed on the
MTM pathway and has resulted in several novel analogs.14–16 The present authors have
shown that the inactivation of the mtmW gene, which codes for the last enzyme in the
MTM biosynthetic pathway, yields the most favorable of the new analogs, MTM SK
(SK) and MTMSDK (SDK).15,16 Both SK and SDK exhibited higher anticancer activity
than the native MTM,15,16 yet their short plasma retention time and low accumulation
in tumors remained to be improved.
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A drug-delivery system is a technique that ensures
drug molecules are delivered to disease lesions at the right
amount and timing by using drug carriers. Nanoparticles
are widely used as drug carriers because large molecules
(.50 kDa) can avoid renal clearance and circulate in the
body for prolonged time in comparison to small molecules.17
Tumors are characterized with leaky blood vessels and
immature lymphatic drainage, which allow nanoparticles
(20–200 nm) to accumulate in tumor tissues.18 Nanoparticles
take advantage of both prolonged plasma retention time and
preferential tumor accumulation to deliver drug payloads to
tumors preferentially.19 Liposomes, dendrimers, and polymer
micelles are nanoparticulate formulations used widely for
tumor-preferential delivery of therapeutic agents. Among
these formulations, polymer micelles offer a versatile platform that can be prepared through self-assembling of block
copolymers in aqueous solutions.20 Self-assembled polymer
micelles possess a core compartment enveloped by a hydrophilic shell. The core-shell structure protects drug payloads
from precipitation, protein adsorption, and enzymatic degradation in the body. The polymer micelles can dissociate
as the core becomes unstable under conditions accompanied
by dilution, drug release, or polymer degradation.21 Polymer
micelles can be stabilized by cross-linking in the core or
shell to avoid premature micelle dissociation during tumorpreferential drug delivery.22,23
In addition to tumor-preferential drug delivery, controlled
drug release is another important factor for nanoparticles
to maximize therapeutic efficacy of drug payloads. Drug
binding linkers are normally designed to degrade in
response to pH, enzymatic activity, light, or heat.24 The
hydrazone bond, involved in many biomolecular events,
is stable at physiological Ph (7.4), yet is cleaved in acidic
conditions (pH , 7.0) in a pH-dependent manner. Such a
unique degradation pattern has been employed to design
pH-controlled drug-delivery systems that can trigger drug
release in intracellular lysosomal compartments (pH 5.0),
following the cellular uptake of drug carriers.25 Tumor tissues
are also acidic (pH 6.5–7.0) due to the inefficient glucose
consumption that massively produces lactic acids.26 Low pH
in tumors is also attributed to high flux at the glyceraldehydes3-phosphate dehydrogenase step of glycolysis.27 These two
factors contribute to tumor acidosis in combination. The
authors of this paper previously demonstrated that polymer
micelles to which drug molecules were conjugated through
acid-sensitive hydrazone linkers could accelerate drug release
in cancer cells and reduce systemic toxicity in animal tumor
models.28 The hydrazone is a chemical bond between ketone
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and hydrazide groups, and thus, drug molecules containing
ketone groups are advantageous to design pH-sensitive drugdelivery systems.29–31
Figure 1 shows the likely chemical structures of MTM
analogs (SK and SDK) and two nanoparticulate formulations (self-assembled and cross-linked polymer micelles)
used in this study. SK and SDK possess one and two ketone
groups, respectively, in their 3-side chains, plus an additional
keto group in the tricyclic ring system. At least one of the
ketone groups is subsequently bound to hydrazide groups of
poly(ethylene glycol)-poly(aspartate hydrazide) [PEG-p(AspHyd)] block copolymers to prepare drug-conjugated polymer
micelles. The acid-labile hydrazone bonds between the block
copolymers and MTM analogs are used to accelerate drug
release in acidic conditions corresponding to tumor tissues
in vivo. Self-assembled and cross-linked micelles are compared to investigate the influence of micelle stability on drugrelease patterns. A549 cell lines (human nonsmall cell lung
cancer) are used to test biological activity of nanoparticulate
MTM formulations. This article, therefore, provides an
insight and understanding of the design, development, and
properties of MTM nanoparticulate formulations for effective cancer therapy.

Materials and methods
Materials

L-aspartic acid β-benzyl ester (BLA), triphosgene, anhydrous hydrazine, N,N′-diisopropylcarbodiimide (DIC),
N-hydroxysuccinimide (NHS), anhydrous tetrahydrofuran
(THF), anhydrous hexane, anhydrous ethyl ether, anhydrous
dimethyl sulfoxide (DMSO), DMSO (molecular biology
grade, $99.9%), DMSO-d6, resazurin sodium salt, acetate
buffer solution, phosphate buffer solution, adipic acid, and
sodium hydroxide (NaOH) were purchased from SigmaAldrich (St Louis, MO). α-Methoxy-ω-amino PEG (5 kDa)
was purchased from NOF Corporation (Tokyo, Japan).
Regenerated cellulose dialysis bags with molecular weight
cutoff (MWCO) 6–8 kDa and Slide-A-Lyzer G2 dialysis cassettes with MWCO 10 kDa, methanol (MeOH), acetonitrile
(ACN), celite, C18 RP silica gel, tryptic soy broth (TSB),
LB broth, Difco™ agar, sucrose, potassium sulfate, magnesium chloride, glucose, casamino acids, yeast extract,
MOPS (3-morpholinopropane-1-sulfonic acid), and trace
elements were purchased from Fisher Scientific (Ottawa,
ON). Streptomyces argillaceus ATCC 12956 was purchased
from ATCC (Manassas, VA). Spectra/Por 6 dialysis tubing
with MWCO 50 kDa was purchased from Spectrum Labs
(Fort Lauderdale, FL).
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Figure 1 Self-assembled and cross-linked polymer micelles as nanoparticulate formulations for MTM analogs.
Abbreviation: MTM, mithramycin.

Biosynthesis of MTM analogs
SK and SDK were produced by an adapted procedure
reported previously.15 Cells of S. argillaceus M7W1 were
plated on R5A agar and grown for 4 days. After 4 days, the
spores were used to inoculate 100 mL of TSB for 24 hours
in an orbital shaker at 28°C, 250 rpm. After 24 hours, 4 mL
of the TSB culture was used to inoculate 40, 100 mL flasks
of R5A media. The cultures were grown for 3 days at 28°C,
250 rpm. After 3 days the cells were harvested and 50 g/L
celite was added to the culture. The cells were removed by
filtration, re-dissolved in MeOH and sonicated for 1 hour to
lyse the cells. After sonication the cells were filtered again
and the MeOH was removed from the filtrate, reconstituted
in water, and loaded onto a 5 cm × 12 cm C18 RP column
equilibrated with 10 column volumes of water. The column
was washed with 10% ACN in water, followed by 20% ACN
in water, and subsequently eluted with 100% ACN. The
filtrate from the initial removal of the cells was also loaded
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onto the C18 column, followed by the same fractionation
procedure. The samples were dried and re-dissolved in 80%
MeOH and water. The compounds were further isolated by
semi-preparative high-performance liquid chromatography
(HPLC).

Block copolymer synthesis
Block copolymers were synthesized as reported previously
(Figure 2).22 In brief, BLA-N-carboxy anhydride (BLA-NCA)
was prepared as a monomer by adding 2.88 g of triphosgene
to 5.0 g β-benzyl-L-aspartate in 100 mL of dry THF at 45°C
until the solution became clear. Anhydrous hexane was added
to the solution slowly to form BLA-NCA crystal, which was
recrystallized at −20°C. PEG was used as a macroinitiator
to conduct the ring-opening polymerization of BLA-NCA,
which produced PEG-(β-benzyl L-aspartate) [PEG-PBLA].
BLA-NCA and PEG were reacted in anhydrous DMSO at
50 mg/mL under N2 for 2 days at 45°C. The PEG-PBLA
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Figure 2 Synthesis of block copolymers, cross-linked block copolymers, and drug conjugates.

block copolymers were isolated from the reaction mixture
by precipitation with anhydrous ethyl ether and subsequently
freeze drying. PEG-PBLA (100 mg/mL) was reacted with
20-fold equivalent hydrazine in DMSO (40°C) for 1 hour to
prepare PEG-p(Asp-Hyd) block copolymers. The materials
were collected by ether precipitation and freeze drying.
The block copolymer compositions were determined by
proton nuclear magnetic resonance spectroscopy (1H-NMR),
which is described as X-Y denoting the molecular weight
of PEG × 10−3 (X) and the number of aspartate repeating
units (Y), respectively.

Synthesis of self-assembled polymer
micelles
MTM analogs were conjugated to the PEG-p(Asp-Hyd)
block copolymers by adding both SK and SDK to the block
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copolymer at 50 weight % in DMSO. The reaction was
allowed to proceed at room temperature for 72 hours, shaking
at 500 rpm. The materials were collected and purified by
repeating ether precipitation. The drug-polymer conjugates
were then re-dissolved in deionized water to form selfassembled micelles. The drug-loaded micelles were collected
by freeze drying.

Synthesis of cross-linked polymer
micelles
Cross-linked polymer micelles were created by cross-linking
PEG-p(Asp-Hyd) 5–40 with adipic acid. PEG-p(Asp-Hyd)
5–40 was dissolved in DMSO to a final concentration of
100 mg/mL. Adipic acid, NHS, and DIC were combined in
DMSO to a mole ratio of 0.5:4:4 times the hydrazide groups
of the block copolymer, respectively, and the reaction mixture
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was added to the block copolymer. The cross-linking reaction
was conducted for 72 hours, stirring at room temperature.
The reaction solution was then dialyzed against DMSO,
followed by 50% DMSO, and finally deionized water. The
solution was freeze dried to collect the purified materials. The
cross-linked micelles were characterized by gel permeation
chromatography (GPC) and 1H-NMR. MTM analogs were
conjugated to cross-linked micelles at a 50 weight % in
DMSO, followed by ether precipitation and freeze drying.

the vehicle- and drug-treated cells at the end of the treatment
period. Cell viability was determined 3 hours later by reading
the fluorescence at 560 nm (excitation wavelength)/590 nm
(emission wavelength). The fluorescence signals were
quantified using a Spectramax M5 plate reader (Molecular
Devices, Sunnyvale, CA) equipped with SoftMax ® Pro
(Molecular Devices) software. Cytotoxicity was determined
by calculating the half maximal inhibitory concentration
(IC50) of each sample.

Micelle characterization

Results
Biosynthesis of SK and SDK

Drug loading efficiency in polymer micelles was determined
by quantifying the absorbance of MTM analogs at 410 nm.
Particle size of the micelles was determined by dynamic
light scattering (DLS) on a Zetasizer Nano-ZS (Malvern
Instruments Ltd, Worcestershire, UK) equipped with a He-Ne
laser light source and 173° angle scattered light collection
configuration.

Drug-release experiments
Drug-release patterns of the self-assembled or cross-linked
polymer micelles were evaluated by using dialysis cassettes
(Slide-A-Lyzer G2, MWCO 10 kDa). Dialysis cassettes
containing 2 mL samples were placed in 4 L of phosphate
buffer solution (10 mM, pH 7.4 or 5.0). The temperature was
maintained at 37°C. An aliquot of 150 µL was taken out of
each dialysis cassette at the time intervals of 0.0, 0.5, 1.0,
3.0, 6.0, 24.0, 48.0, and 72.0 hours. The aliquots taken at
each time point were analyzed by ultraviolet-visible (UV-Vis)
absorbance at 410 nm. All experiments were performed in
triplicate.

Cell toxicity assays
The cytotoxic effects of four MTM nanoparticulate formulations were investigated in comparison to free drugs.
A549 cells were cultured as specified from ATCC at 37°C,
5% CO2. The cells were seeded on a 96-well plate (5000 cells/
well) and allowed to adhere for 24 hours. After 24 hours,
growth media were replaced with fresh media containing
samples at differing concentrations. 1% DMSO (biotechnological grade) was used as a control vehicle to prepare
free drug formulations for SK and SDK. Self-assembled
and cross-linked micelles were used as nanoparticulate
formulations for SK and SDK. The cells were exposed to
samples for 72 hours total (n = 8). Cell viability was assessed
using a resazurin assay that indicates mitochondrial metabolic activity in live cells. A volume of 10 µL of a 1 mM
resazurin solution in phosphate buffered saline was added to
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SK and SDK were successfully produced by the S. argillaceus
M7W1, and isolated through an adapted procedure developed
previously.15 S. argillaceus cells of the M7W1 mutant strain
were plated on R5A agar and allowed to grow until spores
were formed. After 2 days, colonies began to appear on the
plates; after 3 days, spores began to form; and after 4 days,
the majority of the cells were present as spores. Spores from
the plate were used to inoculate an initial culture of TSB
media. The cells grew quickly in TSB media and were ready
to transfer to R5A media after 24 hours. Once transferred to
the R5A growth media, the cells were able to produce the
drug analogs. Initially the media was adjusted to pH 6.85;
however, after the observation of the production, the pH was
adjusted to 7.0. The culture was monitored for the emergence
of the MTM analogs using HPLC. After 24 hours, the presence of MTM analogs or precursors was not readily detected.
After 48 hours, the MTM analogs began to appear; however,
a large population of pre-MTM compounds was still observed.
After 72 hours, the MTM compounds were the dominant
compounds in the culture so the production was stopped.
Much of the population of the MTM analogs was excreted
in the culture media, thus the initial step of the isolation was
to separate out the cells from the media by the addition of a
celite cell-binding resin and subsequent filtration. Once the
cells had been removed, the filtrate was passed over a C18
RP silica gel column to collect the compounds of interest.
The initial washes of 10% and 20% ACN allowed many
of the byproducts to be removed from the sample. Further
fractionation of the culture on the C18 RP column did not aid
in the purification of the individual MTM analogs, so it was
decided to elute all the MTM compounds together to minimize sample loss and excessive dilution. The cells removed
in the initial filtration step did still contain a substantial
amount of SK and SDK, thus to take full advantage of the
production of the analogs the cultured cells were covered in
MeOH and sonicated to lyse the cells and release the drugs.
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Synthesis of polymer micelles
H-NMR showed that PEG-p(Asp-Hyd) was successfully
synthesized as reported previously22 and used to prepare
self-assembled micelles. For cross-linked micelles, the
cross-linking of PEG-p(Asp-Hyd) was confirmed by GPC.
The cross-linked micelles had an average molecular weight
of ∼147 kDa, corresponding to an average of roughly 14 block
copolymers per cross-linked micelle. NMR was also used to
determine the cross-linking percentage. The carboxyl peak
of adipic acid at around 12 ppm disappeared, indicating that
no unreacted or partially reacted adipic acid was present in
the sample. The cross-linking percentage was 12.5%, which
was determined by integrating the newly appeared peaks at
2.1 ppm and 1.5 ppm (α and β CH2 groups of adipic acid)
with respect to the PEG peak at 3.5 ppm.
1

Characterization of MTM-loaded micelles
Following the drug conjugation reaction, ether precipitation
was used to collect the polymers. Initial precipitations
possessed a yellow supernatant corresponding to free drug that
was not entrapped in the micelle structures. Ether precipitations
A

Drug-release experiments
A pH sensitive hydrazone linkage was used to conjugate
MTM analogs to the block copolymers to take advantage of
the acidic tumor environment. To test pH-responsive drugrelease patterns, MTM nanoparticulate formulations were
incubated at pH 7.4 and 5.0. Figure 4 shows that all MTM
nanoparticulate formulations released drugs effectively. At
pH 7.4, self-assembled micelles entrapped more than 50%
of MTM analogs for 24 hours, which will be stable enough
to deliver drugs to tumor tissues following intravenous
injections. Drug release from the self-assembled micelles
was accelerated at pH 5.0, suggesting that SK and SDK will
be released effectively in acidic tumor tissues. Cross-linked
micelles appeared to release drugs more quickly at pH 7.4
than self-assembled micelles, yet retained 40% of drugs for
24 hours. Both SK and SDK were released more rapidly from
cross-linked micelles at pH 5.0.
B

40

Diameter (nm)

were continued until the supernatant remained clear
for several precipitations. The polymers maintained a
yellowish color, after free drugs were removed, indicating
the presence of the MTM analogs. UV-Vis absorption
spectrometry at 410 nm confirmed that both SK and SDK
were successfully entrapped in both the self-assembled
micelles and cross-linked micelles. Drug loading in the selfassembled micelles was 35.4 ± 0.3 and 44.6 ± 2.2 weight %
(wt %) for SK and SDK, respectively. Cross-linked micelles
had an average drug loading of 31.3 ± 0.3 and 42.7 ± 5.3
wt % for SK and SDK, respectively. DLS showed that the
particle size of self-assembled micelles entrapping SK and
SDK was 8.36 ± 3.21 and 12.19 ± 2.77 nm. The particle size
of cross-linked micelles was 29.56 ± 4.67 nm for SK and
30.48 ± 7.00 nm for SDK (Figure 3).
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Cellular debris was removed by again filtering the solution
which was then able to be dried, reconstituted in water, and
loaded on the C18 RP column. After the same wash and
elution steps were performed, a similar solution to the initial
cell filtrate was obtained; however, in a smaller quantity.
The samples could then be loaded and the individual MTM
analogs separated by using semi-preparative HPLC. The
individual peaks were collected and analyzed for purity using
HPLC-mass spectrometry. Both the SK and SDK products
were collected at .95% purity through this procedure and
were stored at −20°C for future use.
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Figure 3 (A) Particle size and (B) drug-entrapment yields.
Abbreviations: SDK, mithramycin SDK; SK, mithramycin SK.
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Abbreviations: SDK, mithramycin SDK; SK, mithramycin SK.

Cell toxicity assays
Cytotoxicity of MTM nanoparticulate formulations was
tested with A549 cells (Figure 5). Free SK and SDK showed
IC50 values of 0.163 ± 0.092 µM and 0.093 ± 0.035 µM,
respectively. IC 50 values of self-assembled micelles
entrapping MTM analogs were 0.262 ± 0.087 µM and
0.282 ± 0.131 µM for SK and SDK, which were 1.6- and
3.0-fold higher than those of free drugs. Interestingly, crosslinked micelles showed IC50 values of 0.073 ± 0.015 µM and
0.075 ± 0.009 µM for SK and SDK, which were 2.2- and

1.2-fold lower than free drugs (Table 1). No toxicity was
observed with block copolymers, self-assembled micelles
and cross-linked micelles alone up to 100 µM (data not
shown).

Discussion
As mentioned above, MTM has been limited clinically by
the severe negative side effects associated with the use of
the drug. However, MTM has shown promise with respect
to treating neurological diseases, glioblastomas, and other
SDK
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Figure 5 The cytotoxicity of free drug and nanoparticulate formulations for SK and SDK against A549 cell lines.
Notes: All points are the average of four measurements ± one standard deviation; error bars not visible are obstructed by the point.
Abbreviations: SDK, mithramycin SDK; SK, mithramycin SK.
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Table 1 A summary of the characteristics and activity of the drug-loaded polymer nanoparticles and that of the free drugs for
comparison
Drug
formulation

SK

SDK

Free

Self-assembled
micelles

Cross-linked
micelles

Free

Self-assembled
micelles

Cross-linked
micelles

IC50 (nM)
Relative efficacy to free drug

163 ± 92
1.00

262 ± 87
0.62

73 ± 15
2.23

93 ± 36
1.00

282 ± 131
0.33

75 ± 9
1.24

Abbreviations: SDK, mithramycin SDK; SK, mithramycin SK.

tumors in addition to showing the ability to inhibit the
multidrug resistance gene, MDR1, in which smaller, less
toxic doses are required.32–37 Recently, MTM was identified
as the lead compound against the Friend leukemia virus
integration 1 (EWS-FLI1) transcription factor.38 EWS-FLI1
is believed to be responsible for malignant transformation
and progression of Ewing sarcoma family tumors and was
widely regarded as undruggable because it is a transcription factor.38 A high-throughput screening of over 50,000
compounds identified MTM as the top candidate from the
screen and greatly reduced and inhibited tumor volume in
Ewing sarcoma family tumors in mouse xenograft models,
and it is planned to reinstitute clinical trials for this application of MTM.38 Additionally, a combinational approach of
MTM with betulinic acid to treat pancreatic cancer showed
the ability to synergistically treat the cancer with a nontoxic
dose of the drugs to produce less discernible side effects.35 As
new treatments and uses for MTM continue to be uncovered,
the development and optimization of a compatible drugdelivery system will be necessary.
The potential of MTM has been enhanced by the discovery of two new analogs produced through engineering
of the MTM biosynthetic pathway. These analogs, SK and
SDK, are a result of the inactivation of the mtmW gene and
have shown improved activity compared with that of the
native MTM. The biosynthesis and isolation of the SK and
SDK analogs are pivotal as larger quantities of the drug
will be required for testing and eventually clinical use. SK
and SDK are produced alongside two other compounds, a
demycarosyl-MTM SK and MTM SA (SA). The SA analog
shows decreased anticancer activity and the demycarosylMTM SK shows activity similar to that of the native MTM,
thus neither are the preferred products of the mutant strain.
Initially, a culture pH of 6.85 was used for the production
of the drugs. These conditions allowed for good production
of the SK, but a large amount of SA and very little SDK
were also being observed. The formation of SK, SDK, and
SA are a result of the spontaneous rearrangement of the
immediate product MTM DK, resulting from the MtmOIV
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reaction of the biosynthetic pathway.15,16 It has been shown
by in-vitro work that the major product of the conversion of
premithramycin B by MtmOIV can be shifted to SDK at a
pH of 8.25.39 In an effort to improve the production of SDK
from the culture, the pH of the media was adjusted to 7.0.
It was hoped that the adjustment of the pH, although small,
would still allow optimal growth of the M7W1 mutant strain
and production of the MTM analogs, but that the production
yield of SDK would be improved. Increasing the pH of the
growth media to 7.0 confirmed the hypothesis and increased
the production yield of SDK. Increasing the pH also did not
appear to adversely affect the production of SK. This will be
critical as the production of the analogs is scaled up to meet
the clinical demands.
As the drive for more specific and efficient chemotherapeutic options continues, delivery systems will undoubtedly
play a pivotal role in their development and advancement. To
that end, these novel MTM formulations still need to resolve
issues such as low tumor accumulation, poor bioavailability, and short plasma retention time to be further explored
clinically. Drug-delivery systems are expected to address
these concerns by delivering MTM preferentially to tumors.
Liposomal formulations have been previously tested, but the
release of MTM analogs from liposomes has proved to be
difficult.40 Studies suggest that polymer micelles will offer
an alternative platform for the delivery of MTM, not only
delivering the drug to tumors but also controlling the drugrelease patterns efficiently. It has been demonstrated that
block copolymers offer a versatile platform in this direction.
In this study, MTM analogs (SK and SDK) were entrapped
in polymer micelles through an acid-labile hydrazone conjugation between drug molecules and micelle-forming block
copolymers. Prepared MTM nanoparticulate formulations
appeared to combine the favorable characteristics of drugdelivery systems with the ability to entrap drugs at high
yields and to control the drug release at the area of interest.
SK and SDK have one and two ketone groups on the
side chain. These ketone groups offer a prime location for
the conjugation of the drugs to the PEG-p(Asp-Hyd) block
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copolymers through the hydrazone bond. Self-assembled
micelles showed higher drug loading of SDK (44.6 wt %)
than SK (35.4 wt %), suggesting that the second ketone group
of the SDK side chain could facilitate drug loading rather than
saturating the drug-binding sites. The particle size of selfassembled micelles was 44% larger with SDK (12.19 nm)
than SK (8.36 nm), which is consistent with the increased
SDK loading in micelles. The average particle size of crosslinked micelles was 26.79 nm in the absence of drugs. Crosslinked micelles were 29.56 and 30.48 nm after entrapping
SK and SDK, respectively. Even though the particle size was
retained, cross-linked micelles entrapped 31.3 wt % SK and
42.7 wt % SDK, which were comparable to the amount of
drugs that self-assembled micelles entrapped.
Again, an acid labile hydrazone bond was used to
conjugate the drugs to the block copolymers so the release
of the drugs from the nanoformulations was investigated
at both the physiological pH of 7.4 and an intracellular
endosome or lysosome pH of 5.0. Effective drug release
was observed in all MTM nanoparticulate formulations
tested improving on previous attempts of MTM delivery
with liposomes. MTM analogs were released slowly from
polymer micelles at pH 7.4 regardless of formulations. The
drug release was accelerated at pH 5.0 (Figure 4), which
is advantageous to release drugs in acidic tumor tissues.
After 72 hours, however, the amount of drugs released was
similar at both pH values. MTM nanoparticulate formulations are expected to minimize drug leakage in the blood
and maximize therapeutic efficacy by releasing drugs in
tumor tissues rapidly.
MTM nanoparticulate formulations were shown to be
effective to suppress cancer cell growth, indicating that
MTM analogs were delivered in a biologically active form.
Self-assembled micelles entrapping MTM analogs showed
lower cytotoxic effects than free drugs as expected, but
interestingly, cross-linked micelles enhanced drug efficacy
up to 2.2-fold (Table 1). Although further investigation is
necessary to elucidate the mechanism behind this intriguing phenomenon, the results of this study suggest that drug
release in the early stage would not play a crucial role in
determining cellular response to MTM analogs as all nanoparticulate formulations released a similar amount of drugs
between 1 and 3 hours. Drug release at pH 7.4 rather than 5.0
appeared to be the major factor that determines cytotoxicity.
MTM analogs were effective to suppress cancer cell growth
in order of cross-linked SK micelles, cross-linked SDK
micelles, self-assembled SK micelles, and self-assembled
SDK micelles, which is consistent with the drug-release
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patterns at pH 7.4, whereas all nanoparticulate formulations
released drugs similarly at pH 5.0, which does not explain
differential cytotoxicity observed in A549. Therefore, it is
more reasonable to assume that drugs released from micelles
at pH 7.4 comprise the major drug population that involved
in cell killing, while intracellular drug release (pH 5.0) has
less effect on overall cytotoxicity of MTM nanoparticulate
formulations. However, detailed intracellular mechanisms
on how cells respond to MTM nanoparticulate formulations
(eg, particle size and intracellular drug distribution) should
be investigated further in the future.
Cross-linked micelles had a 12.5% cross-linking yield,
which was high enough to tether block copolymer chains
before and after entrapping drugs without causing agglomeration between particles. In spite of the high cross-linking
yield, cross-linked micelles entrapped and released MTM
analogs effectively. Importantly cross-linked micelles
released drugs more quickly than self-assembled micelles,
implicating that MTM analogs could be entrapped in the
vicinity rather than at the center of the micelle core. The
rapid drug release from cross-linked micelles can be also
attributed to the rigid environment in the cross-linked core
of the micelles. Cross-linking the core could allow for a
more porous and less tightly packed core in the micelles so
that drug molecules can maneuver more easily out of the
core. In contrast, self-assembled micelles have a flexible
core that can continue to pull block copolymers to keep the
particle stable as drugs are released. This may explain why
drug release from self-assembled micelles was slower than
cross-linked micelles.
Cytotoxic effects of MTM nanoparticulate formulations
revealed an interesting phenomenon that can be used to
design potent drug-delivery systems. Unlike self-assembled
micelles that decreased the toxicity of MTM analogs, crosslinked micelles showed a higher potency against A549 cancer
cells than free drugs. The exact mechanism and reason for
the improved efficacy is yet to be confirmed, although the
more stable cross-linked micelles could aid in the drug’s
persistence in the cells, allowing more drugs to interact with
the therapeutic targets in the cell. In addition to the known
mechanism of the MTM family of compounds in which they
bind the GC rich DNA present in Sp family of promoters, the
expression of the gene encoding for a multidrug resistance
efflux pump, MDR1, has also been shown to be inhibited by
MTM and some of it derivatives.36,37 This would make the
MTM nanoparticulate formulations excellent candidates for
combinational therapy attacking hard-to-treat, multidrugresistant cancer cell lines. Future studies will explore
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whether these results translate in vivo and dig deeper into
the reasoning behind the improved activity.

Conclusion
Nanoparticulate formulations for controlled delivery of MTM
analogs, SK and SDK, were prepared by using self-assembled
or cross-linked polymer micelles from PEG-p(Asp-Hyd)
block copolymers to which drugs were conjugated through
acid-labile hydrazone bonds. With recent interest in MTM
for several novel treatment approaches, a compatible delivery
system with ability to selectively deliver the drug to the area
of interest would be advantageous. Both the SK and SDK
analogs offer higher anticancer activity compared with MTM
and thus were investigated with respect to a compatible
delivery system. SK and SDK were successfully loaded into
polymer micelles and demonstrated a pH-dependent release
profile, accelerating drug release at pH 5.0. By cross-linking
the micelles, the size of the particles was increased without
significantly affecting the drug loading. Both the selfassembled and cross-linked structures were able to deliver the
drugs in the biologically active form and efficiently kill the
human nonsmall cell lung cancer cell line (A549). The crosslinked micelles interestingly improved the cytotoxicity of
MTM analogs, even compared with the free drugs. The ability
to prepare delivery platforms without losing any biological
activity will streamline the development of therapeutic
options, and these results conclude that nanoparticulate
formulations offer prime candidates to pave the path for SK,
SDK, and other MTM analogs to be explored further with
animal models and potentially in the clinical field.
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